Literature DB >> 24754584

Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients.

Jessica Jürgens1, Walburga Engel-Riedel, Alexander Prickartz, Corinna Ludwig, Oliver Schildgen, Ramona-Liza Tillmann, Erich Stoelben, Michael Brockmann, Verena Schildgen.   

Abstract

A total of three cases with novel constellations regarding mutation patterns in non-small-cell lung cancer (NSCLC) are reported. The mutation patterns that are observed are novel and unexpected. First, a combined simultaneous KRAS mutation and EML4-ALK translocation, both in the main tumor and a bone metastasis, were observed, these mutations are assumed to mutually exclude each other. A further two cases include a father and a daughter, both of whom are suffering from NSCLC with different EGFR mutation patterns. A common cause was assumed; however, could not be deduced to mutations in the KRAS, BRAF and EGFR genes. The aforementioned cases are important, as it must be taken into account that mutations previously assumed to be exclusive can occur in combination, may influence the clinical outcome and may require different therapy compared with single mutated tumors. It has to be discussed whether diagnostic algorithms need to be adapted. The cases of father and daughter show that further unknown factors can influence development of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24754584     DOI: 10.2217/fon.13.194

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  7 in total

1.  EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.

Authors:  Sema Bircan; Huseyin Baloglu; Zafer Kucukodaci; Ahmet Bircan
Journal:  Med Oncol       Date:  2014-06-29       Impact factor: 3.064

Review 2.  Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.

Authors:  Till Plönes; Walburga Engel-Riedel; Erich Stoelben; Christina Limmroth; Oliver Schildgen; Verena Schildgen
Journal:  J Pers Med       Date:  2016-01-15

3.  Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.

Authors:  Yuping Li; Shanshan Su; Guoping Cai; Quan Lin; Ying Zhou; Jinsheng Ouyang; Bicheng Chen; Junru Ye; Xiuling Wu; Chengshui Chen
Journal:  Mol Clin Oncol       Date:  2017-06-29

Review 4.  Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Authors:  Giuseppe Lo Russo; Martina Imbimbo; Giulia Corrao; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Laura Botta; Nicoletta Zilembo; Filippo de Braud; Marina Chiara Garassino
Journal:  Oncotarget       Date:  2017-04-26

5.  Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.

Authors:  Ilija Nenadić; Jeanine Staber; Susanne Dreier; Guus Simons; Verena Schildgen; Michael Brockmann; Oliver Schildgen
Journal:  Cancers (Basel)       Date:  2017-07-11       Impact factor: 6.639

6.  Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country.

Authors:  Tiago F Andreis; Bruno S Correa; Fernanda S Vianna; Fernanda De-Paris; Marina Siebert; Sandra Leistner-Segal; Eriza C Hahn; Jane M Ulbrich; Luis F R Rivero; Francine H De Oliveira; Vinícius Lorandi; Patricia Ashton-Prolla; Gabriel S Macedo
Journal:  J Glob Oncol       Date:  2019-09

7.  Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature.

Authors:  Nishitha Thumallapally; Sara Parylo; Adarsh Vennepureddy; Uroosa Ibrahim; Alisa Sokoloff
Journal:  World J Oncol       Date:  2018-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.